This website uses technical, customisation and analytical cookies, both first-party and third-party, to anonymously facilitate browsing and analyse statistics on use of the website. Learn more
Search results
-
New Immuno-Oncology Solutions (NIOS): Aligning Stakeholders in the Biotech Industry
Vroom, Govert; Maribel Berges; Sastre Boquet, IsaacCase SM-1701-EEntrepreneurship, Innovation and Change, StrategyThis case focuses on a small biotech company (NIOS), located in Barcelona, Spain, that is developing a new immune-oncology product for treating pancreatic cancer. The drug that the company is developing has recently finished Phase I of clinical trials successfully and is now preparing for Phase II and III. At this point, the CEO is approached by her former PhD director, a university professor, who asks if the company is interested in licensing a ...Starting at €8.20
-
Building a Unified Collaboration Strategy at Genpact: SolutionXchange and Beyond
Káganer, Evgeny; Carmel, Erran; Tatarinov, KatherineCase SI-190-EInformation Technologies, Innovation and Change, Knowledge and CommunicationGenpact launched SolutionXchange with the goal of bringing together clients and industry experts to collaborate in solving business process management (BPM) challenges. To date, the initiative has been a success - helping solve more than 200 BPM-related challenges. Genpact is committed to taking SolutionXchange (SCx) to the next level and expanding its scale significantly to become a global BPM community of choice for experts and clients to share...Starting at €8.20
-
New Immuno-Oncology Solutions (NIOS) - Teaching Note: Aligning stakeholders in the biotech industry
Vroom, Govert; Maribel Berges; Sastre Boquet, IsaacTeaching Note SMT-136-EEntrepreneurship, Innovation and Change, StrategyThis case focuses on a small biotech company (NIOS), located in Barcelona, Spain, that is developing a new immune-oncology product for treating pancreatic cancer. The drug that the company is developing has recently finished Phase I of clinical trials successfully and is now preparing for Phase II and III. At this point, the CEO is approached by her former PhD director, a university professor, who asks if the company is interested in licensing a ...Starting at €0.00